Merck Outlines Access Plan for Investigational Monthly HIV Prevention Pill
MT Newswires Live
Jul 24
Merck (MRK) said Friday it unveiled an early access strategy for alimatravir, its investigational once-monthly oral HIV prevention pill, if it receives regulatory approval.
The company said the plan includes royalty-free licensing agreements with seven generic drugmakers to supply 129 low- and middle-income countries, investments in manufacturing capacity, and support for regional production in Africa and Latin America.
Merck said it is implementing the strategy while Phase 3 trials are still underway to accelerate access following potential approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.